LRCXLAM RESEARCH CORPORATIONMega cap · $412.59B · FY ending 2025-06-29
$329.92-5.83% · 2026-07-13 · EOD
53/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality97
wide moat · ROIC 56%Value34
P/E 79.5 · 69% of 12-mo rangeMomentum74
golden · price above 200-daySmart Money9
selling · 6 funds · 0P/11S insidersMixed trendGolden crossAbove 200-day
vs S&P 500+55.5%
6-mo excess Trailing performance1M +2.5%
3M +25.1%
6M +64.2%
YTD +78.3%
1Y +226.5%
P/E vs its last 12 months (our price history): 22.9 low → 104.4 high
Current price sits at the 69th percentile of that window — mid-range. We only compare against the price history we own (no paid multi-year multiples — nothing invented).
Wide moat — ROIC 56%
Piotroski F8/9
fundamental strength Altman ZSafe
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 10%. Annual figures from SEC XBRL.
Dividend & capital return
Payout ratio21.5%
comfortable Shareholder yield1.1%
dividends + buybacks Annual figures from SEC cash-flow statements. Shareholder yield = total cash returned ÷ market cap.
Net selling0P / 11S insiders · 6 funds hold · 0 Congress buys
Recent insidersARCHER TIMOTHY · President and CEOSELL$11.7M
BRANDT ERIC · DirectorSELL$19.1M
BRANDT ERIC · DirectorSELL$20.0M
Fernandes Neil J · Senior Vice PresidentSELL$2.4M
Fund holders (13F)GMO (Jeremy Grantham)$1.48B3.8% of book
Tiger Global
Ahealth · 89/100
Self-fundingSelf-funding — profitable · generates cash
No red flags from its filings.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.